Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Antineoplastic Agents, Hormonal (therapeutic use); Breast Neoplasms (drug therapy, pathology); Female; Humans; Obesity; Postmenopause; Receptor, ErbB-2
BACKGROUND: Despite benefits of endocrine therapy (ET) for patients with hormone-receptor (HR)-positive breast cancer, many patients do not initiate or discontinue ET against recommendations. METHODS: We identified variables associated with ET initiation and continuation, analyzing pooled data from two longitudinal studies at a National Cancer Institute comprehensive cancer center in St. Louis, Missouri. The sample included 533 women with newly diagnosed, non-metastatic, HR-positive breast cancer who completed interviews at enrollment and 6, 12, and 24 months after definitive surgical treatment. Logistic regression models estimated the adjusted odds ratio and 95% confidence interval (aOR [95% CI]) for each of self-reported ET initiation by the 12-month interview and continuation for ≥12 months by the 24-month interview in association with self-reported diabetes, elevated depressed mood, menopausal-symptom severity and obesity, adjusting for race, age, insurance status, chemotherapy, and radiation therapy. RESULTS: Overall, 81.4% (434/533) of patients initiated ET, and 86.5% (371/429) continued ET ≥12 months. Patients with diabetes had lower odds of initiating ET (0.50 [0.27-0.91]). Patients reporting greater menopausal-symptom severity had lower odds of continuing ET (0.72 [0.53-0.99]). CONCLUSION: Efforts to increase ET initiation among patients with diabetes and better manage severe menopausal symptoms among ET users might promote ET continuation. CLINICAL TRIAL INFORMATION: ClinicalTrials.gov : #NCT00929084.
Digital Object Identifier (DOI)
Cho, Beomyoung; Pérez, Maria; Jeffe, Donna B.; Kreuter, Matthew W.; Margenthaler, Julie A.; Colditz, Graham A.; and Liu, Ying, "Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer" (2022). UNF Faculty Research and Scholarship. 3194.